REMUS — Remus Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapMomentum Trap

Annual income statement for Remus Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	247	450	2,125	6,204	8,536
Cost of Revenue
Gross Profit	124	236	482	875	1,114
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	208	350	1,856	5,765	7,997
Operating Profit	39.2	101	269	438	540
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	45.5	114	318	473	592
Provision for Income Taxes
Net Income After Taxes	33.9	85	260	384	462
Minority Interest
Net Income Before Extraordinary Items
Net Income	33.9	85	215	291	370
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	33.9	85	215	291	370
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.87	10.4	17.9	24.5	39.2
Dividends per Share